Sharecare, the health tech company that helps to improve care quality, drive better outcomes, and lower costs across the healthcare ecosystem, ...

Fiserv, Inc. (NYSE: FI), a leading global provider of payments and financial services technology solutions, today reported financial results for the third quarter of 2024. Third ...

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at the 2024 Society for Immunotherapy of Cancer Meeting taking place November ...

Third quarter revenues of $2.49 billion, up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from 2023 F ...

Cadence Bank (NYSE: CADE) (the Company), today announced financial results for the quarter ended September 30, 2024. Highlights for the third ...

Powell Max Limited (Nasdaq: PMAX) (the "Company" or "Powell Max"), a financial communications services provider headquartered in Hong Kong, today announced ...

DMC Global (NASDAQ: BOOM) ("DMC" or the "Company") today provided an update on its business conditions and revised its third quarter financial guidance.

Solid profitability and decisions to increase capacity Q3 2024 highlights - Order intake for the rolling 12-month period decreased by 12% to SEK 19,646 million (22,362), with organic growth of -8%.

Third quarter operating income of $203.3 million increased from $200.6 million the same quarter last year, primarily from contributions from business acquisitions offset by weaker market conditions an ...

FLYHT Shareholders Entitled to Elect Cash or FTG Shares, Subject to Pro-ration, at a 41% PremiumTransaction Will Allow FLYHT Shareholders to Participate in Significant Potential Future Upside with Pro ...

TORONTO, ON / ACCESSWIRE / October 21, 2024 / PowerBand Solutions Inc. (TSXV:PBX)(OTC PINK:PWWBF)(Frankfurt:1ZVA) ("PowerBand" or the "Company"), a fintech platform targeting auto finance and speciali ...

Remain on track to initiate registrational THRIVE-3 trial in 1Q' 2025 NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transfo ...